On April 30, 2015, the pCODR Expert Review Committee (pERC) issued initial recommendations for Romidepsin (Istodax) for Peripheral T-Cell Lymphoma (PTCL).
pERC recommended funding romidepsin (Istodax) conditional on the cost effectiveness being improved to an acceptable level. The committee specified that funding should be for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are ineligible for transplant and who have undergone previous systemic therapy. Additionally, patients should have an ECOG PS of 0-2 and romidepsin treatment should be continued until disease progression or unacceptable toxicity.
Lymphoma Canada thanks all those who completed surveys or participated in interviews to appeal to the provincial governments to provide funding for this important treatment.
Once Health Canada has approved a cancer drug for use in Canada, the country’s provinces and territories must decide if the drug will be eligible for public reimbursement. The CADTH pan-Canadian Oncology Drug Review (pCODR) plays an important role in their decision-making processes.
pCODR conducts thorough and objective evaluations of clinical, economic, and patient evidence on cancer drugs, and uses this evaluation to make recommendations to the provinces and territories in Canada to help them decide whether they will provide funding for new cancer treatments.